2019

London, UK

2018 Speakers

Expand/Collapse

David Solomon
Chief Executive Officer
Akari Therapeutics

David Horn Solomon is the Chief Executive Officer of Akari Therapeutics (NASDAQ: AKTX): He joined the Company in August 2017. Prior to joining the Company, Dr. Solomon was Managing Partner of SundCapital ApS, a healthcare investment fund based in Copenhagen, Denmark, a position he held since 2016. From 2015 to 2016, Dr. Solomon was Chief Executive Officer of Bionor A/S (OSLO: BIONOR) and from 2008 to 2015 he was the Chief Executive Officer of Zealand Pharma A/S (Nasdaq: ZEAL). Since 2015, Dr. Solomon has served as a Board Member and Chair of the Remuneration and Compensation Committee of TxCell S.A. (NYSE Euronext: TXCL) and Dr. Solomon previously served on the boards of Onxeo SA (NYSE Euronext and NASDAQ: ONXEO) from 2011 to 2017 and Promosome, LLC from 2014 to 2017. Dr. Solomon previously held senior positions at Carrot Capital and Vital Sensors, and served as a faculty member at Columbia University’s College of Physicians and Surgeons. Dr. Solomon studied at Cornell University’s Weil Medicine and its Graduate School of Medical Science/ Sloan Kettering Division in New York where he received his Ph.D. in 1991.

Day Two

Thursday March 22nd, 2018

12.30 | Coversin: The Role in the Treatment of Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome

Simon Read
CSO
Ra Pharma

Day Two

Thursday March 22nd, 2018

12.00 | RA101495 and Macrocyclic Peptides for Disorders of Complement Regulation

Sandip Panicker
Executive Director
Bioverativ Inc.

Sandip Panicker, Ph.D., is Executive Director of Complement Research at Bioverativ Inc., where he oversees the discovery and pre-clinical efforts on complement programs. Dr. Panicker is the scientific champion behind BIVV009, a first-in-class humanized monoclonal antibody that inhibits the classical pathway specific serine protease, C1s. Sandip has also been involved with the clinical study designs and regulatory submissions and interactions that have led to the orphan and breakthrough designation status of BIVV009 for the treatment of cold agglutinin disease.

Day Two

Thursday March 22nd, 2018

14.00 | Development of BIVV009 for the Treatment of Patients with Primary Cold Agglutinin Disease

Jessy Alexander
Professor
University at Buffalo

My research is aimed at understanding the roles of the innate and adaptive immune systems in health and disease. The organs of my interest are the two specialized filtration units, glomeruli and blood-brain barrier, of the kidney and brain respectively. Recently, our understanding of the immune system has undergone a substantial paradigm shift: researchers now recognize that the innate immune system, the body’s first line of defense, assesses the level of danger of a particular event and initiates an adaptive immune response that subsequently confers protection. My studies focus on the role of an important arm of the innate immune system, the complement cascade in inflammatory conditions such as glomerulonephritis and lupus. For both disease conditions, the perfect therapy remains an enigma. Using a gamut of techniques, we are attempting to define the molecular mechanisms involved and the resulting behavioral aberrations. Once molecular targets are identified, therapeutic strategies will be defined. I teach in UB’s Discovery Seminar Program, which is geared for first- and second-year undergraduates. The seminars are taught in a small-class environment to students who share common goals and similar interests, in ways that enhance their academic, civic and personal growth. I teach “The Yin-Yang of Biology” and “Brain: Day and Night,” and I teach as well in UB’s Honors College. I also mentor students through the CLIMB-PRO program. One of my recent students conducted research that resulted in a publication in the journal Kidney International.

Day One

Wednesday March 21st, 2018

11.30 | C5a/C5aR1 Signaling Alters Blood-Brain Barrier Integrity and Brain Function in Systemic Lupus Erythematosus

Michael Holers
Scoville Professor & Head, Division of Rheumatology
University of Colorado

Day One

Wednesday March 21st, 2018

16.00 | Chairman’s Closing Remarks & Close of Day 1

14.00 | Panel: Determining which Portion of the Complement Pathway is the Most Effective Intervention Point for Specific Diseases

10.00 | Panel: Developing a Roadmap for the Next Generation of Efficacy Assessment Techniques and Complement Diagnostics

09.00 | Chairman’s Opening Remarks

Day Two

Thursday March 22nd, 2018

15.00 | Chairman’s Closing Remarks & Close of Summit

10.00 | Advances in Understanding of Disease Pathogenesis in Rheumatoid Arthritis and Systemic Lupus Erythematosus Open Up New Opportunities for Complement Therapeutics

09.25 | Chairman’s Opening Remarks

Ashley Frazer-Abel
Director
Exsera Biolabs

Day One

Wednesday March 21st, 2018

10.00 | Panel: Developing a Roadmap for the Next Generation of Efficacy Assessment Techniques and Complement Diagnostics

09.30 | Taking Complement Testing from Diagnostics to Drug Development: What is well suited for one may not do well for the other.

Andrea Tenner
Professor of Molecular Biology & Biochemistry
University of California

Day One

Wednesday March 21st, 2018

12.00 | Inhibition of C5aR1 Alters Microglial Polarisation and Rescues Neuron Damage and Cognitive Loss in a Mouse Model of Alzheimer’s Disease

Kai Höhlig
Director Preclinical Research
Aptarion Biotech AG

Day One

Wednesday March 21st, 2018

14.00 | Panel: Determining which Portion of the Complement Pathway is the Most Effective Intervention Point for Specific Diseases

12.30 | Inhibition of C5a to Enhance the Efficacy of Cancer Immunotherapies

Richard Smith
Director, Protein Therapeutics Laboratory
King’s College London

Tom Mollnes
Professor of Immunology and Leader, Complement Research Group
University of Oslo

Day One

Wednesday March 21st, 2018

10.00 | Panel: Developing a Roadmap for the Next Generation of Efficacy Assessment Techniques and Complement Diagnostics

Day Two

Thursday March 22nd, 2018

10.30 | Dual blockade of complement C3/C5 and TLR/CD14 as a Novel Treatment Approach for Sepsis and SIRS.

Erik Hack
CSO
Prothix

Day One

Wednesday March 21st, 2018

14.00 | Panel: Determining which Portion of the Complement Pathway is the Most Effective Intervention Point for Specific Diseases

Anna Schubart
Investigator III
Novartis

Day Two

Thursday March 22nd, 2018

14.30 | Development of an Alternative Complement Pathway Inhibitors and Assessment of the Potential Infection Risk